Targeting the Cell Surface in Small Cell Lung Cancer and other Neuroendocrine Carcinomas-Targeting the Cell Surface in Small Cell Lung Cancer and other Neuroendocrine Carcinomas

Targeting the Cell Surface in Small Cell Lung Cancer and other Neuroendocrine Carcinomas - Video

Video Transcription

Video Summary

In the ISLC webinar, experts Dr. Anne-Marie Dingemans discussed emerging treatments targeting DLL-3 in small-cell lung cancer and neuroendocrine carcinomas, focusing on T-cell engagers like Tarlatumab. Dr. Dingemans highlighted that DLL-3 is a promising target mostly expressed in lung cancer, making it ideal for DLC-3 T-cell engagers. These T-cell engagers have shown early and durable responses in clinical trials, with a significant portion of patients experiencing prolonged benefits. However, despite encouraging data, not all patients respond, leading to an interest in identifying biomarkers to better select responsive patients.<br /><br />The webinar also touched on advances in antibody-drug conjugates (ADCs), which offer targeted chemotherapy. Despite positive responses, their systemic toxicity remains a concern. The discussion also considered potential combinations of T-cell engagers with ADCs and chemotherapy to enhance treatment outcomes while managing side effects.<br /><br />A key discussion point was the potential role of these treatments in transformed lung cancers, particularly those with high DLL-3 expression. Participants stressed the importance of continuing research to refine patient selection through biomarkers and enhance therapeutic efficacy. The session concluded with an emphasis on collaborative efforts to better understand and treat these aggressive cancers effectively.

Asset Subtitle

Video

Keywords

DLL-3

T-cell engagers

small-cell lung cancer

neuroendocrine carcinomas

Tarlatumab

antibody-drug conjugates

biomarkers

transformed lung cancers

collaborative research